Research
Hormonal
Peripheral metabolic dysregulation (obesity, diabetes) leads to brain insulin resistance and Alzheimer's pathology through BBB permeabilization, neuroinflammation, and AGE-RAGE signaling.
Managing your weight, blood sugar, and metabolic health is crucial for brain health. Obesity and diabetes increase the risk of Alzheimer's by causing inflammation and insulin resistance in the brain. Focus on a healthy diet and exercise to protect your brain.
GoodSupportsHIGH confidence
lipidemic dysregulation in metabolic disorders may lead to BBB permeabilization to FFAs, triggering a cascade of events leading to activation of glial cells, and neuroinflammation. In parallel, increased AGE levels in hyperglycemia may contribute to RAGE-mediated disruption of BBB integrity and further promote brain pathology leading to AD.
Why this rating
Supported by extensive epidemiological and preclinical data, though human mechanistic details are still being elucidated.
Source
Insulin Resistance in Alzheimer's Disease
Laís S. S. Ferreira et al. · Frontiers in Neuroscience · 2018
DOI 10.3389/fnins.2018.00830
narrative_reviewCited 220×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intranasal insulin administration improves memory and cognitive function in patients with mild cognitive impairment (MCI) and early Alzheimer's disease, particularly in non-ApoE4 carriers and women.Good
- GLP-1 receptor agonists (exendin-4 and liraglutide) improve memory deficits, reduce amyloid plaque load, and restore insulin signaling in Alzheimer's disease models.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →